Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

BACKGROUND: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively. METHODS: Neutralizing antibody titers to the 4 dengue serot...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Infect Dis
Главные авторы: Moodie, Zoe, Juraska, Michal, Huang, Ying, Zhuang, Yingying, Fong, Youyi, Carpp, Lindsay N, Self, Steven G, Chambonneau, Laurent, Small, Robert, Jackson, Nicholas, Noriega, Fernando, Gilbert, Peter B
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2018
Предметы:
Major Articles and Brief Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5854020/
https://ncbi.nlm.nih.gov/pubmed/29194547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jix609
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы